Our top pick for
Building a portfolio
Cyanotech Corporation is a packaged foods business based in the US. Cyanotech Corporation shares (CYAN) are listed on the NASDAQ and all prices are listed in US Dollars. Cyanotech Corporation employs 95 staff and has a trailing 12-month revenue of around USD$32.1 million.
|Latest market close||USD$3.04|
|52-week range||USD$1.82 - USD$3.45|
|50-day moving average||USD$2.8855|
|200-day moving average||USD$2.6245|
|Wall St. target price||USD$14|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$0.09|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-01-14)||-5.88%|
|1 month (2020-12-22)||2.36%|
|3 months (2020-10-21)||0.33%|
|6 months (2020-07-21)||36.94%|
|1 year (2020-01-21)||18.75%|
|2 years (2019-01-18)||3.04|
|3 years (2018-01-19)||3.8|
|5 years (2016-01-21)||4.992|
Valuing Cyanotech Corporation stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Cyanotech Corporation's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Cyanotech Corporation's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 34x. In other words, Cyanotech Corporation shares trade at around 34x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Cyanotech Corporation's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$2.6 million.
The EBITDA is a measure of a Cyanotech Corporation's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||USD$32.1 million|
|Operating margin TTM||2.01%|
|Gross profit TTM||USD$12.7 million|
|Return on assets TTM||1.23%|
|Return on equity TTM||3.7%|
|Market capitalisation||USD$18.5 million|
TTM: trailing 12 months
There are currently 2,042 Cyanotech Corporation shares held short by investors – that's known as Cyanotech Corporation's "short interest". This figure is 43.6% down from 3,619 last month.
There are a few different ways that this level of interest in shorting Cyanotech Corporation shares can be evaluated.
Cyanotech Corporation's "short interest ratio" (SIR) is the quantity of Cyanotech Corporation shares currently shorted divided by the average quantity of Cyanotech Corporation shares traded daily (recently around 34033.333333333). Cyanotech Corporation's SIR currently stands at 0.06. In other words for every 100,000 Cyanotech Corporation shares traded daily on the market, roughly 60 shares are currently held short.
However Cyanotech Corporation's short interest can also be evaluated against the total number of Cyanotech Corporation shares, or, against the total number of tradable Cyanotech Corporation shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Cyanotech Corporation's short interest could be expressed as 0% of the outstanding shares (for every 100,000 Cyanotech Corporation shares in existence, roughly 0 shares are currently held short) or 0.0007% of the tradable shares (for every 100,000 tradable Cyanotech Corporation shares, roughly 1 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Cyanotech Corporation.
Find out more about how you can short Cyanotech Corporation stock.
We're not expecting Cyanotech Corporation to pay a dividend over the next 12 months.
Cyanotech Corporation's shares were split on a 1:4 basis on 6 November 2006. So if you had owned 4 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Cyanotech Corporation shares – just the quantity. However, indirectly, the new 300% higher share price could have impacted the market appetite for Cyanotech Corporation shares which in turn could have impacted Cyanotech Corporation's share price.
Over the last 12 months, Cyanotech Corporation's shares have ranged in value from as little as $1.82 up to $3.45. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Cyanotech Corporation's is 0.3995. This would suggest that Cyanotech Corporation's shares are less volatile than average (for this exchange).
Cyanotech Corporation engages in the cultivation, production, and sale of natural products derived from microalgae for the health and human nutrition markets worldwide. The company's products include BioAstin Hawaiian Astaxanthin, a dietary antioxidant, which is used as a human nutraceutical and functional food ingredient to support and maintain the body's natural inflammatory response, enhance skin, and support eye and joint health; and Hawaiian Spirulina Pacifica, a nutrient-rich dietary supplement that is used for extra energy, a strengthened immune system, cardiovascular benefits, and as a source of antioxidant carotenoids. Cyanotech Corporation sells its products as packaged consumer products through distributors, retailers, and online channels, and direct to consumers, as well as in bulk form to manufacturers, formulators, and distributors. The company was founded in 1983 and is headquartered in Kailua-Kona, Hawaii.
Everything we know about the NLS Pharmaceutics Ltd IPO, plus information on how to buy in.
Everything we know about the GitLab IPO, plus information on how to buy in.
Everything we know about the Longeveron LLC IPO, plus information on how to buy in.
Everything we know about the Signify Health Inc IPO, plus information on how to buy in.
Everything we know about the Biophytis SA IPO, plus information on how to buy in.
Everything we know about the NexImmune Inc IPO, plus information on how to buy in.
Everything we know about the Adagene Inc IPO, plus information on how to buy in.
Everything we know about the Cloopen Group Holding Limited IPO, plus information on how to buy in.
Everything we know about the Decipher Biosciences Inc IPO, plus information on how to buy in.
Everything we know about the Proterra IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.